MCID: DDN001
MIFTS: 52

Duodenal Ulcer

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Duodenal Ulcer

MalaCards integrated aliases for Duodenal Ulcer:

Name: Duodenal Ulcer 12 54 44 15 17 70 32
Stress Ulcer 12 54 70
Curling Ulcer 12 70
Stress Ulcer of Stomach 70
Duodenal Ulcer Disease 54
Curling's Ulcers 12
Duodenal Ulcers 15

Classifications:



External Ids:

Disease Ontology 12 DOID:1724
ICD9CM 34 532
MeSH 44 D004381
NCIt 50 C26755
SNOMED-CT 67 155691003 39755000
ICD10 32 K26
UMLS 70 C0010474 C0013295 C0400807 more

Summaries for Duodenal Ulcer

MalaCards based summary : Duodenal Ulcer, also known as stress ulcer, is related to gastrointestinal ulceration, recurrent, with dysfunctional platelets and peptic ulcer perforation. An important gene associated with Duodenal Ulcer is HRH2 (Histamine Receptor H2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Esomeprazole and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include pancreas, bone and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Duodenal Ulcer

Diseases in the Duodenal Ulcer family:

Duodenal Ulcer Due to Antral G-Cell Hyperfunction

Diseases related to Duodenal Ulcer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 911)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal ulceration, recurrent, with dysfunctional platelets 33.0 S100A8 HRH2 GAST
2 peptic ulcer perforation 31.2 S100A8 HRH2
3 duodenitis 31.0 TNF S100A8 INS GAST CCK
4 hernia, hiatus 31.0 HRH2 GAST CYP2C19
5 cholecystitis 30.9 TLR4 S100A8 CCK
6 zollinger-ellison syndrome 30.9 SST SCT HRH2 GRP GAST
7 duodenogastric reflux 30.9 SST SCT GAST CCK
8 active peptic ulcer disease 30.9 SST HRH2 CYP2C19
9 peptic ulcer disease 30.8 TNF SST SCT S100A8 IL1RN IL1B
10 cholelithiasis 30.8 SST INS GAST CCK
11 dumping syndrome 30.8 SST SCT INS GAST CCK
12 opisthorchiasis 30.8 TNF IL1B CXCL8
13 obstructive jaundice 30.7 TNF TLR4 IL6 GRP CXCL8
14 helicobacter pylori infection 30.7 TNF NOD1 IL1RN IL1B IL10 CYP2C19
15 varicose veins 30.6 TNF IL6 CXCL8
16 pernicious anemia 30.5 SST SCT GAST
17 neurotic disorder 30.5 TNF INS IL6
18 gastric ulcer 30.5 TNF SST S100A8 PSCA IL6 IL1RN
19 purpura 30.4 TNF IL6 IL10
20 esophagitis 30.4 TNF IL6 IL1B IL10 HRH2 GAST
21 human cytomegalovirus infection 30.4 IL6 IL1B CXCL8
22 peptic esophagitis 30.4 TNF S100A8 IL6 IL1B HRH2 GAST
23 peritonitis 30.4 TNF TLR4 IL6 IL1B IL10 CXCL8
24 appendicitis 30.4 TNF TLR4 IL6 IL1B IL10 CXCL8
25 arteriovenous malformation 30.3 TNF IL6 IL1B
26 sarcoidosis 1 30.3 TNF LTA IL1RN IL1B
27 bile reflux 30.3 SCT S100A8 GAST CCK
28 exanthem 30.3 TNF IL6 IL1B IL10 CXCL8
29 intestinal perforation 30.3 TNF TLR4 IL6
30 spondyloarthropathy 1 30.3 TNF TLR4 IL6 IL1RN
31 pustulosis of palm and sole 30.3 TNF IL1RN CXCL8
32 portal hypertension 30.3 TNF TLR4 SST INS CXCL8
33 atrophic gastritis 30.3 TNF SST S100A8 IL6 IL1RN IL1B
34 gastrinoma 30.2 SST SCT INS GRP GAST
35 cholangitis 30.2 TNF TLR4 IL6 IL10 CXCL8
36 gastric neuroendocrine neoplasm 30.2 SST GAST
37 biliary dyskinesia 30.2 SST SCT CCK
38 haemophilus influenzae 30.2 TNF CXCL8
39 postgastrectomy syndrome 30.2 SST INS GAST
40 amebiasis 30.2 TNF IL1B IL10 CXCL8
41 somatoform disorder 30.1 IL6 IL1RN IL1B
42 gastroenteritis 30.1 TNF IL6 IL1RN IL1B IL10 HRH2
43 spondylitis 30.1 TNF LTA IL6 IL1B IL10
44 status asthmaticus 30.0 IL1RN IL10 CXCL8
45 pancreatitis 30.0 TNF SST SCT INS IL6 IL1B
46 pancreatic steatorrhea 30.0 SCT CCK
47 autoimmune pancreatitis 30.0 TNF TLR4 IL10
48 duodenum cancer 30.0 SST SCT GAST
49 constipation 30.0 TNF SST INS IL6 GRP GAST
50 pharyngitis 30.0 TNF IL6 IL1B CXCL8

Graphical network of the top 20 diseases related to Duodenal Ulcer:



Diseases related to Duodenal Ulcer

Symptoms & Phenotypes for Duodenal Ulcer

GenomeRNAi Phenotypes related to Duodenal Ulcer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CXCL8 IL10 IL1B LTA NOD1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CXCL8 IL10 IL1B LTA NOD1 SST

MGI Mouse Phenotypes related to Duodenal Ulcer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.97 CCK GAST IL10 IL1B IL1RN IL6
2 digestive/alimentary MP:0005381 9.86 GAST HRH2 IL10 IL6 INS SST
3 neoplasm MP:0002006 9.5 GAST IL10 IL1B IL6 PSCA TLR4
4 skeleton MP:0005390 9.32 IL10 IL1B IL1RN IL6 INS LTA

Drugs & Therapeutics for Duodenal Ulcer

Drugs for Duodenal Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
4
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
7
Sucralfate Approved Phase 4 54182-58-0
8
Pantoprazole Approved Phase 4 102625-70-7 4679
9
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
10
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
11
Famotidine Approved Phase 4 76824-35-6 3325
12
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
13
Ranitidine Approved, Withdrawn Phase 4 66357-59-3, 66357-35-5, 82530-72-1 3001055
14
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
15
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
16 Anti-Bacterial Agents Phase 4
17 Antibiotics, Antitubercular Phase 4
18 Anti-Infective Agents Phase 4
19 Antiparasitic Agents Phase 4
20 Antiprotozoal Agents Phase 4
21 Respiratory System Agents Phase 4
22 Anti-Infective Agents, Local Phase 4
23 Citrate Phase 4
24 Monoamine Oxidase Inhibitors Phase 4
25 diuretics Phase 4
26 Antimalarials Phase 4
27
Bismuth Phase 4 7440-69-9 16682734 105143
28 Expectorants Phase 4
29 Bismuth tripotassium dicitrate Phase 4
30 Gastrointestinal Agents Phase 4
31 Antacids Phase 4
32 Proton Pump Inhibitors Phase 4
33 Anti-Ulcer Agents Phase 4
34 Neurotransmitter Agents Phase 4
35 Histamine H2 Antagonists Phase 4
36
Histamine Phosphate Phase 4 51-74-1 65513
37 Histamine Antagonists Phase 4
38 Ranitidine bismuth citrate Phase 4
39
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
40
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
41
Racepinephrine Approved Phase 2, Phase 3 329-65-7 838
42
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
43
Naproxen Approved, Vet_approved Phase 3 22204-53-1 1302 156391
44
Rabeprazole Approved, Investigational Phase 2, Phase 3 117976-89-3 5029
45
Clarithromycin Approved Phase 3 81103-11-9 84029
46
Ketoprofen Approved, Vet_approved Phase 3 22071-15-4 3825
47
Rebamipide Approved, Investigational Phase 2, Phase 3 90098-04-7
48
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
49
Cimetidine Approved, Investigational Phase 3 51481-61-9 2756
50
Clopidogrel Approved Phase 3 120202-66-6, 113665-84-2 60606

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
2 An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours Completed NCT00428701 Phase 4 Esomeprazole Sodium
3 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
4 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
5 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study Completed NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
6 Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy Completed NCT02718261 Phase 4 Pantoprazole;Saline 0.9% (matching placebo)
7 Phase IV Study of Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial Completed NCT00708149 Phase 4 lansoprazole OD;placebo
8 A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study Completed NCT00702871 Phase 4 Ranitidine;Sucralfate
9 Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit Completed NCT00633035 Phase 4 esomeprazole 40 mg;famotidine 20 mg
10 Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) Completed NCT02467621 Phase 4 Pantoprazole
11 Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer Completed NCT00239551 Phase 4 Prevacid
12 Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease Recruiting NCT03667703 Phase 4 Famotidine;Placebo
13 Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery Terminated NCT00839488 Phase 4 pantoprazole 40 mg iv;famotidine 20 mg iv
14 A Prospective, Randomized, Double-Blind Protocol to Compare the Efficacy of Lansoprazole to Ranitidine in Healing Pre-Existing and/or Preventing the Development of Gastroduodenal Stress Ulceration and Postoperative Bleeding in Patients Undergoing Elective Coronary Artery Bypass Graft or Cardiac Valve Replacement Surgery Terminated NCT00220909 Phase 4 Lansoprazole
15 Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori Unknown status NCT00149084 Phase 3 Lansoprazole, clarithromycin, amoxicillin
16 Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection Unknown status NCT00197418 Phase 2, Phase 3 rabeprazole, amoxicillin, clarithromycin, metronidazole
17 A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00542789 Phase 3 Esomeprazole;Placebo
18 A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use Completed NCT00595517 Phase 3 Esomeprazole 20 mg
19 A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taking Low Dose Aspirin Completed NCT00175032 Phase 3 Lansoprazole and naproxen and aspirin;Celecoxib and aspirin
20 Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial- Completed NCT01397448 Phase 2, Phase 3 E3810;E3810;Teprenone
21 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial- Completed NCT01398410 Phase 2, Phase 3 Rabeprazole;Rabeprazole
22 A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer Completed NCT01452724 Phase 3 TAK-438;Placebo;Lansoprazole;Placebo
23 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Rabeprazole-Controlled,Multicenterand Phase3 Trial in China in China Completed NCT02847455 Phase 2, Phase 3 5 mg ilaprazole;10 mg ilaprazole;10 mg Rabeprazole
24 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase3 Trial in China Completed NCT00952978 Phase 3 10 mg ilaprazole;20 mg omeprazole
25 A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter Pylori Infection Completed NCT03050359 Phase 3 TAK-438;Lansoprazole;TAK-438 Placebo;Lansoprazole Placebo;Bismuth-Containing Quadruple Therapy
26 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy Completed NCT01568398 Phase 3 TAK-438
27 A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy Completed NCT01568385 Phase 3 TAK-438
28 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01452763 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
29 A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID). Completed NCT01452750 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
30 A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use Completed NCT01069939 Phase 3 Esomeprazole;Placebo
31 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID) Completed NCT01456260 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
32 A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin Completed NCT01456247 Phase 3 TAK-438;Placebo;TAK-438;Placebo;Lansoprazole;Placebo
33 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug Completed NCT00787254 Phase 3 Lansoprazole;Gefarnate
34 A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk Completed NCT00629928 Phase 3 Esomeprazole;Esomeprazole;Placebo
35 Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions Completed NCT00971581 Phase 3 FDC KETOPROFEN+OMEPRAZOLE
36 An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
37 A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA) Completed NCT00441727 Phase 3 Esomeprazole 40 mg;Esomeprazole 20 mg;Placebo
38 Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study Completed NCT02166008 Phase 2, Phase 3 Repamipide;Placebo
39 High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment Completed NCT00132171 Phase 3 Sequential therapy
40 Phase IIb Randomized, Double Blind, Two Arm, Controlled Clinical Trial of Mycobacterium W in Combination With Standard Therapy Versus Standard Therapy Alone in Sepsis Completed NCT02330432 Phase 2, Phase 3
41 Effect of Intravenous Esomeprazole Versus Cimetidine in Prevention of Stress Ulcer Prophylaxis in Chinese Seriously Ill Patients - a Randomized, Double-blind, Parallel-group Study Completed NCT02157376 Phase 3 Esomeprazole;Cimetidine
42 Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU Completed NCT02290327 Phase 3 Pantoprazole;Placebo
43 An Open Label, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy and Safety of D961H for the Maintenance Therapy Following Initial Treatment in Japanese Paediatric Patients With Reflux Esophagitis and for the Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer in Japanese Paediatric Patients Treated With Non-steroidal Anti-inflammatory Drugs or Low-dose Aspirin Recruiting NCT03553563 Phase 3 D961H capsule 10mg;D961H sachet 10mg
44 A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers. Not yet recruiting NCT04215653 Phase 3 Anaprazole Sodium;Rabeprazole;Rabeprazole Placebo;Anaprazole Sodium Placebo
45 A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease Terminated NCT00557921 Phase 3 CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin;Plavix (clopidogrel 75 mg) and aspirin
46 A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin. Terminated NCT00762359 Phase 3 Lansoprazole;Gefarnate
47 Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase2 Trial in China Completed NCT00953381 Phase 2 5 mg ilaprazole;10 mg ilaprazole;20 mg ilaprazole;20 mg omeprazole
48 A Phase 2,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers. Completed NCT04503629 Phase 2 Anaprazole Sodium;Anaprazole Sodium;Rabeprazole sodium
49 Glutaminergic and Histaminergic Pathway Modulation in Acute Ischemic Stroke as an Effective Neuroprotection Strategy. Completed NCT02142712 Phase 2 Diphenhydramine;Pantoprazole;Famotidine;Dextromethorphan
50 MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001) Completed NCT00543868 Phase 2 MK0782

Search NIH Clinical Center for Duodenal Ulcer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Cimetidine
Cimetidine Hydrochloride
dihydroxyaluminum sodium carbonate
Esomeprazole
Esomeprazole magnesium
esomeprazole sodium
Esomeprazole Strontium
Famotidine
lansoprazole
magaldrate
Magnesium Hydroxide
Maprotiline
Maprotiline Hydrochloride
MILK OF MAGNESIA
Nizatidine
Omeprazole
Omeprazole 2 MG/ML Oral Suspension
Omeprazole magnesium
Prazepam
rabeprazole
Sucralfate

Cochrane evidence based reviews: duodenal ulcer

Genetic Tests for Duodenal Ulcer

Anatomical Context for Duodenal Ulcer

MalaCards organs/tissues related to Duodenal Ulcer:

40
Pancreas, Bone, Liver, Heart, Kidney, Small Intestine, Colon

Publications for Duodenal Ulcer

Articles related to Duodenal Ulcer:

(show top 50) (show all 17361)
# Title Authors PMID Year
1
Associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease in Chinese Han population. 54 61
19804405 2010
2
Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. 61 54
19930551 2009
3
homB status of Helicobacter pylori as a novel marker to distinguish gastric cancer from duodenal ulcer. 54 61
19710266 2009
4
Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. 54 61
19318661 2009
5
Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study. 61 54
19399945 2009
6
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 61 54
18612816 2009
7
The prevalence of the duodenal ulcer promoting gene (dupA) in Helicobacter pylori isolates varies by ethnic group and is not universally associated with disease development: a case-control study. 54 61
19338650 2009
8
The prevalence of cagA and cagE genes in Helicobacter pylori strains isolated from different patient groups by polymerase chain reaction. 61 54
19260336 2008
9
Toll-like receptor (TLR2, TLR4 and TLR5) gene polymorphisms and Helicobacter pylori infection in children with and without duodenal ulcer. 61 54
18809506 2008
10
IL-4 -588C>T polymorphism and IL-4 receptor alpha [Ex5+14A>G; Ex11+828A>G] haplotype concur in selecting H. pylori cagA subtype infections. 54 61
18179773 2008
11
Effects of Helicobacter pylori Infection on gastric mucin expression. 54 61
18097286 2008
12
Stress ulcer prophylaxis in hospitalized patients not in intensive care units. 61 54
17592004 2007
13
Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with Helicobacter pylori-induced duodenal ulcer and gastritis. 61 54
17309748 2007
14
Helicobacter pylori cagA, vacA and iceA genotypes in northern Thai patients with gastric disease. 61 54
17539287 2007
15
Association between interleukin-1 gene polymorphisms and Helicobacter pylori infection in gastric carcinogenesis in a Chinese population. 61 54
17295877 2007
16
The risk of pancreatic cancer in patients with gastric or duodenal ulcer disease. 54 61
17044024 2007
17
Analysis of serum antibody profile against H pylori VacA and CagA antigens in Turkish patients with duodenal ulcer. 61 54
17106939 2006
18
[Expression of gastrin, somatostatin, PCNA and Fas-L in the mucosa of gastric antrum of children with chronic gastritis and duodenal ulcer]. 54 61
17229384 2006
19
Detection of Helicobacter pylori cagA gene in gastric biopsies, clinical isolates and faeces. 61 54
16912439 2006
20
CagA positivity and its association with gastroduodenal disease in Turkish children undergoing endoscopic investigation. 54 61
16868800 2006
21
Interaction between IL1B gene promoter polymorphisms in determining susceptibility to Helicobacter pylori associated duodenal ulcer. 54 61
16550552 2006
22
Assay of gastrin and somatostatin in gastric antrum tissues of children with chronic gastritis and duodenal ulcer. 54 61
16610039 2006
23
[The part of the hormone-cyclase system in achieving the therapeutic effect of hydrochloric acid secretion inhibitors at the duodenal ulcer]. 54 61
16866262 2006
24
Development of a novel method to detect Helicobacter pylori cagA genotype from paraffin-embedded materials: comparison between patients with duodenal ulcer and gastric cancer in young Japanese. 54 61
16543737 2006
25
IL1RN polymorphism and cagA-positive Helicobacter pylori strains increase the risk of duodenal ulcer in children. 54 61
16183821 2005
26
No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. 54 61
16164697 2005
27
[Association of trefoil factor 1 expression with gastric mucosa injuries and gastric cancer]. 61 54
16174594 2005
28
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology. 54 61
16110845 2005
29
Relationship between trefoil factor 1 expression and gastric mucosa injuries and gastric cancer. 54 61
15849833 2005
30
The humoral immuneresponse to Helicobacter pylori infection in children with gastrointestinal symptoms. 54 61
15866217 2005
31
Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors. 54 61
15762883 2005
32
Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. 61 54
15652446 2005
33
[Gastrin-17 level in the omeprazole treatment of duodenal ulcer]. 61 54
17378383 2005
34
Topographic expression of MUC5AC and MUC6 in the gastric mucosa infected by Helicobacter pylori and in associated diseases. 54 61
16325508 2005
35
TNF/LTA polymorphisms and risk for gastric cancer/duodenal ulcer in the Korean population. 61 54
15381184 2004
36
Genetic polymorphism of interleukin-8 (IL-8) is associated with Helicobacter pylori-induced duodenal ulcer. 61 54
15627645 2004
37
High prevalence of multiple strain colonization of Helicobacter pylori in Korean patients: DNA diversity among clinical isolates from the gastric corpus, antrum and duodenum. 61 54
15053036 2004
38
Helicobacter pylori-induced immunological responses in patients with duodenal ulcer and in patients with cardiomyopathies. 61 54
15571071 2004
39
The diversity of vacA and cagA genes of Helicobacter pylori in East Asia. 61 54
14734191 2004
40
Lewis antigen expression in gastric mucosa of children: relationship with Helicobacter pylori infection. 61 54
14676601 2004
41
Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. 61 54
14615467 2003
42
Association of interleukin 1 gene family polymorphisms with duodenal ulcer disease. 61 54
14632761 2003
43
[Effect of quamatel on neutrophil properties, parameters of lipid peroxidation and the antioxidant defense system in blood of patients with duodenal ulcer and pancreatitis]. 54 61
14743716 2003
44
History in our lifetime: the changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists. 54 61
14567455 2003
45
Local and peripheral cytokine response and CagA status of Helicobacter pylori-positive patients with duodenal ulcer. 61 54
14656687 2003
46
DNA-level characterization of Helicobacter pylori strains from patients with overt disease and with benign infections in Bangladesh. 61 54
12734242 2003
47
Helicobacter pylori genotypes and expression of gastritis in erosive gastro-oesophageal reflux disease. 61 54
12795459 2003
48
Significance of an exaggerated meal-stimulated gastrin response in pathogenesis of Helicobacter pylori-negative duodenal ulcer. 54 61
12741450 2003
49
Lack of association between pro-inflammatory genotypes of the interleukin-1 (IL-1B -31 C/+ and IL-1RN *2/*2) and gastric cancer/duodenal ulcer in Korean population. 61 54
12788304 2003
50
[Association between Helicobacter pylori virulence and duodenal ulcer disease in patients from Hong Kong in China]. 61 54
12697114 2003

Variations for Duodenal Ulcer

Expression for Duodenal Ulcer

Search GEO for disease gene expression data for Duodenal Ulcer.

Pathways for Duodenal Ulcer

Pathways related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 TNF TLR4 S100A8 NOD1 LTA INS
2
Show member pathways
13.72 TNF TLR4 LTA INS IL6 IL1RN
3
Show member pathways
13.45 TNF TLR4 LTA IL6 IL1B IL10
4
Show member pathways
13.41 TNF NOD1 LTA IL6 IL1RN IL1B
5
Show member pathways
13.34 TNF LTA IL6 IL1B IL10 CXCL8
6
Show member pathways
13.25 TNF TLR4 IL6 IL1B IL10 CXCL8
7
Show member pathways
12.99 TNF TLR4 IL6 IL1B CXCL8 CXCL1
8
Show member pathways
12.9 TNF LTA INS IL6 IL1B IL10
9
Show member pathways
12.84 TNF TLR4 IL6 IL1B CXCL8
10
Show member pathways
12.8 TNF TLR4 NOD1 IL6 IL1B CXCL8
11
Show member pathways
12.75 TNF TLR4 LTA IL6 IL1B
12
Show member pathways
12.65 TNF TLR4 IL6 IL1B IL10
13
Show member pathways
12.64 TNF TLR4 IL6 IL1B IL10
14
Show member pathways
12.63 TNF IL6 IL1B IL10 CXCL1
15 12.61 TNF NOD1 IL1RN IL1B IL10
16
Show member pathways
12.52 SST SCT HRH2 GAST CCK
17
Show member pathways
12.49 TNF TLR4 NOD1 IL6 IL1B CXCL8
18 12.47 TNF TLR4 NOD1 IL1B CXCL8
19
Show member pathways
12.39 TNF S100A8 IL6 IL1B CXCL8 CXCL1
20
Show member pathways
12.38 TNF TLR4 IL6 IL1B CXCL8
21
Show member pathways
12.38 TNF LTA IL6 IL10 CXCL8 CXCL1
22
Show member pathways
12.37 TNF INS IL6 IL1B
23
Show member pathways
12.33 TNF LTA IL6 IL1B IL10 CXCL8
24
Show member pathways
12.31 TNF TLR4 IL6 CXCL8
25 12.31 TNF TLR4 IL6 IL1B IL10
26
Show member pathways
12.3 TNF TLR4 IL1B IL10
27
Show member pathways
12.29 TNF IL6 IL1RN IL1B CXCL8
28 12.28 TNF TLR4 NOD1 IL6 IL1B CXCL8
29
Show member pathways
12.26 TNF IL6 IL1B IL10
30
Show member pathways
12.24 TNF TLR4 IL6 IL1B CXCL8
31 12.16 TNF TLR4 IL6 IL1B IL10 CXCL8
32 12.16 TNF SST IL6 IL1RN IL1B IL10
33 12.09 TNF TLR4 IL6 IL1B CXCL8 CXCL1
34 12.06 TNF IL6 IL1B IL10 CXCL8
35 12.05 TNF LTA IL6 IL1B CXCL1
36 12.02 TNF TLR4 LTA IL1B CXCL8 CXCL1
37 12.01 INS IL6 IL1B CXCL8 CXCL1
38 11.98 TNF IL6 IL1B CXCL8
39 11.96 TNF TLR4 IL6 IL1B CXCL8 CXCL1
40
Show member pathways
11.94 TLR4 IL6 CXCL8 CXCL1
41 11.87 TNF LTA IL1B IL10
42 11.83 TNF IL6 IL1B IL10
43 11.78 TNF TLR4 LTA IL6 IL10
44
Show member pathways
11.74 TNF IL6 IL1B CXCL8
45 11.73 TNF IL6 IL1B CXCL8
46
Show member pathways
11.73 TNF TLR4 LTA IL6 IL1B IL10
47 11.71 TNF TLR4 IL6 IL1B IL10 CXCL8
48 11.64 INS IL6 CXCL8
49 11.63 TNF TLR4 LTA
50 11.57 TNF TLR4 IL1B

GO Terms for Duodenal Ulcer

Cellular components related to Duodenal Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNF SST SCT S100A8 PSCA LTA
2 extracellular space GO:0005615 9.5 TNF SST SCT S100A8 LTA INS

Biological processes related to Duodenal Ulcer according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.15 SST SCT INS HRH2 GRP GAST
2 positive regulation of gene expression GO:0010628 10.13 TNF TLR4 INS IL6 IL1B CXCL8
3 negative regulation of cell proliferation GO:0008285 10.09 SST IL6 IL1B IL10 CXCL8 CXCL1
4 defense response to bacterium GO:0042742 10.04 TNF TLR4 S100A8 NOD1 IL10
5 cell-cell signaling GO:0007267 10.02 SST LTA INS IL1B
6 signal transduction GO:0007165 10 TLR4 NOD1 LTA INS IL6 IL1RN
7 defense response GO:0006952 9.99 TNF NOD1 CXCL8 CXCL1
8 cytokine-mediated signaling pathway GO:0019221 9.98 TNF IL6 IL1RN IL1B IL10 CXCL8
9 activation of MAPK activity GO:0000187 9.97 TNF TLR4 NOD1 IL1B
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 TNF IL6 IL1B IL10
11 response to lipopolysaccharide GO:0032496 9.95 TLR4 S100A8 LTA IL1B IL10
12 defense response to Gram-positive bacterium GO:0050830 9.94 TNF NOD1 LTA IL6
13 positive regulation of inflammatory response GO:0050729 9.91 TNF TLR4 S100A8 IL1B
14 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.91 TNF S100A8 NOD1 CCK
15 neutrophil chemotaxis GO:0030593 9.9 S100A8 CXCL8 CXCL1
16 positive regulation of JNK cascade GO:0046330 9.9 TNF TLR4 NOD1 IL1B
17 regulation of insulin secretion GO:0050796 9.89 TNF IL6 IL1B
18 negative regulation of interleukin-6 production GO:0032715 9.89 TNF TLR4 IL10
19 humoral immune response GO:0006959 9.87 TNF LTA IL6
20 positive regulation of cytokine production GO:0001819 9.87 TNF INS IL10
21 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TNF TLR4 NOD1 IL1B
22 cellular response to lipopolysaccharide GO:0071222 9.87 TNF TLR4 IL6 IL1B IL10 CXCL8
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF TLR4 IL1B
24 response to glucocorticoid GO:0051384 9.86 TNF IL6 IL1RN IL10
25 positive regulation of chemokine production GO:0032722 9.85 TNF TLR4 IL6
26 acute-phase response GO:0006953 9.85 INS IL6 IL1RN
27 positive regulation of interleukin-6 production GO:0032755 9.85 TNF TLR4 NOD1 IL6 IL1B
28 positive regulation of JAK-STAT cascade GO:0046427 9.84 TNF IL6 IL10
29 positive regulation of interferon-gamma production GO:0032729 9.84 TNF TLR4 LTA IL1B
30 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF TLR4 IL1B
31 negative regulation of neurogenesis GO:0050768 9.81 TNF IL6 IL1B
32 positive regulation of interleukin-1 beta production GO:0032731 9.81 TNF TLR4 NOD1 IL6
33 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.8 TNF TLR4 IL6
34 positive regulation of nitric-oxide synthase activity GO:0051000 9.8 TNF NOD1 INS
35 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 TNF TLR4 S100A8 NOD1 INS IL6
36 negative regulation of lipid catabolic process GO:0050995 9.77 TNF INS IL1B
37 positive regulation of interleukin-8 production GO:0032757 9.77 TNF TLR4 NOD1 IL6 IL1B
38 embryonic digestive tract development GO:0048566 9.76 TNF SCT CXCL8
39 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.75 TNF IL1B IL10
40 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 IL10
41 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.73 IL1RN IL10
42 response to molecule of bacterial origin GO:0002237 9.72 IL10 CXCL8
43 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.72 TNF TLR4
44 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
45 positive regulation of peptide hormone secretion GO:0090277 9.71 INS GRP
46 negative regulation of lipid storage GO:0010888 9.71 TNF IL6
47 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
48 positive regulation of glial cell proliferation GO:0060252 9.71 TNF LTA IL6 IL1B
49 positive regulation of lipid catabolic process GO:0050996 9.7 SCT IL1B
50 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.7 IL6 IL1RN

Molecular functions related to Duodenal Ulcer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 TLR4 SCT LTA GRP CXCL1
2 hormone activity GO:0005179 9.35 SST SCT INS GAST CCK
3 cytokine activity GO:0005125 9.23 TNF LTA IL6 IL1RN IL1B IL10

Sources for Duodenal Ulcer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....